Gold prices slip as stronger dollar, Fed rate uncertainty weigh
Investing.com - BofA Securities has reiterated its Buy rating and $92.00 price target on Merus N.V. (NASDAQ:MRUS), identifying the company as one of its top picks for the remainder of 2025. The stock, currently trading at $66.79, has shown remarkable momentum with a 46.45% gain over the past six months, according to InvestingPro data.
The firm highlighted the performance of Merus’s lead asset petosemtamab, which it says has "continued to exceed expectations with compelling efficacy and safety" in head and neck squamous cell carcinoma (HNSCC) and is advancing into registrational development.
BofA Securities indicated it will focus closely on initial data from the phase 2 study in metastatic colorectal cancer (mCRC) in the second half of 2025, describing this as "strategically important for expanding petosemtamab beyond HNSCC."
The research firm expects strong momentum to continue into 2026 with two pivotal phase 3 readouts in HNSCC.
BofA currently models risk-adjusted peak sales for petosemtamab of $2.5 billion in 2037 for first-line treatment and $947 million in 2035 for second-line treatment in HNSCC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.